TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Average Price Target of $63.00

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $63.00.

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. HC Wainwright restated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, September 21st. Jefferies Financial Group restated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research note on Monday, June 22nd. Finally, B. Riley Financial upped their price objective on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th.

Insider Buying and Selling

In other news, Director Laurence Charney sold 5,000 shares of TG Therapeutics stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares of the company’s stock, valued at $9,268,454.40. This trade represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 8.87% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TGTX. EverSource Wealth Advisors LLC raised its stake in TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 365 shares during the period. Hantz Financial Services Inc. boosted its stake in shares of TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares during the period. Pingora Partners LLC increased its holdings in shares of TG Therapeutics by 31.2% during the 4th quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 500 shares during the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of TG Therapeutics during the 2nd quarter worth approximately $96,000. Finally, Allworth Financial LP bought a new stake in TG Therapeutics in the 2nd quarter valued at $128,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $56.19 on Friday. The firm has a market capitalization of $8.60 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 2.41 and a beta of 1.67. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The business has a fifty day simple moving average of $53.72 and a 200 day simple moving average of $46.04. TG Therapeutics has a one year low of $26.76 and a one year high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The business had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. During the same period in the previous year, the business posted $0.17 earnings per share. TG Therapeutics’s revenue was up 70.2% on a year-over-year basis. Sell-side analysts expect that TG Therapeutics will post 0.92 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell diseases and autoimmune disorders. The company’s research and development programs are centered on therapies that target B cells, which play an important role in several immune-mediated conditions.

TG Therapeutics’ principal product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.